Expertise in
24
conditions

Dr. Brenda M. Latowsky

Dermatology
Brenda Latowsky M.D. P.L.C.
20201 N Scottsdale Healthcare Dr, Suite 260, 
Scottsdale, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
24
conditions
Brenda Latowsky M.D. P.L.C.
20201 N Scottsdale Healthcare Dr, Suite 260, 
Scottsdale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brenda Latowsky is a Dermatologist in Scottsdale, Arizona. Dr. Latowsky is highly rated in 24 conditions, according to our data. Her top areas of expertise are Eosinophilic Pustular Folliculitis, Grover's Disease, Sunburn, and Warts. Dr. Latowsky is currently accepting new patients.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in MA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Freedom Life
  • INSURANCE PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
MercyCare
  • EPO
  • HMO
Moda Health
  • EPO
  • PPO
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

BRENDA LATOWSKY M.D. P.L.C.
20201 N Scottsdale Healthcare Dr, Suite 260, Scottsdale, AZ 85255
Other Locations
BRENDA LATOWSKY M.D. P.L.C.
7125 E Lincoln Dr, Suite A101, Paradise Valley, AZ 85253

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
Enrollment Status: Recruiting
Publish Date: May 04, 2025
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Magnetic Muscle Stimulation of Abdominal Muscle
Magnetic Muscle Stimulation of Abdominal Muscle
Enrollment Status: Terminated
Publish Date: July 02, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis
A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2023
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
Proof of Concept (POC) Study of the Soliton's Acoustic Scar Reduction (ASR) Treatment Using Rapid Acoustic Pulse (RAP) Device for the Treatment of Keloid Scar
Proof of Concept (POC) Study of the Soliton's Acoustic Scar Reduction (ASR) Treatment Using Rapid Acoustic Pulse (RAP) Device for the Treatment of Keloid Scar
Enrollment Status: Completed
Publish Date: September 28, 2021
Intervention Type: Device
Study Phase: Not Applicable
Multi-Center Study of the Soliton Rapid Acoustic Pulse (RAP) Device for the Treatment of Cellulite
Multi-Center Study of the Soliton Rapid Acoustic Pulse (RAP) Device for the Treatment of Cellulite
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis
A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis
Enrollment Status: Completed
Publish Date: February 18, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 14 Less Clinical Trials

14 Total Publications

NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.
NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.
Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: September 09, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Aaron R. Mangold
Dermatology
Expertise in
25
conditions
Dr. Aaron R. Mangold
Dermatology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (9.4 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Mangold is a Dermatologist in Scottsdale, Arizona. Dr. Mangold is highly rated in 25 conditions, according to our data. His top areas of expertise are Lichen Planus, Granuloma Annulare, Cutaneous T-Cell Lymphoma (CTCL), and Mycosis Fungoides. Dr. Mangold is currently accepting new patients.

Expertise in
19
conditions
Dr. Mark R. Pittelkow
Dermatology
Expertise in
19
conditions
Dr. Mark R. Pittelkow
Dermatology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (9.4 miles away)
480-301-8000
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Pittelkow is a Dermatologist in Scottsdale, Arizona. Dr. Pittelkow has been practicing medicine for over 46 years is highly rated in 19 conditions, according to our data. His top areas of expertise are Lichen Planus, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, and T-Cell Lymphoma. Dr. Pittelkow is currently accepting new patients.

Expertise in
106
conditions
Dr. Gary A. Mccracken
Dermatology
Expertise in
106
conditions
Dr. Gary A. Mccracken
Dermatology

Center For Dermatology PLLC

14275 N 87th St, Suite 110, 
Scottsdale, AZ 
 (4.1 miles away)
480-905-8485
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gary Mccracken is a Dermatologist in Scottsdale, Arizona. Dr. Mccracken is highly rated in 106 conditions, according to our data. His top areas of expertise are Rosacea, Seborrheic Keratosis, Actinic Keratosis, and Warts. Dr. Mccracken is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Latowsky's expertise for a condition
ConditionClose
      View All 24 Advanced Conditions
      View All 50 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile